arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

Sonoma Pharmaceuticals, Inc.

SNOA
$1.08 ▼ -0.03 (-2.25%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sonoma Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8M
Dividend Yield —
Revenue Growth 36.7% ↗
Op. Margin -12.6% ↗
ROIC -73.8% ↗
FCF / Share $-2.45 ↘
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.53M
↑ +36.7% —
Net Income Profit after all expenses
$-3.17M
↑ +8.2% —
Operating Margin Operating profit as % of sales
-12.6%
↑ +51.5% 9th
FCF / Share Free cash flow per share
$-2.45
↓ -1709.4% —
Long-Term Debt Long-term obligations
$1.31M
— —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns ↓
7
Financial Health ↓
45
Cash Quality ↑
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 64 quarters